Skip to main content
Clinical Trials/NCT00265369
NCT00265369CompletedPhase 3

Comparative Efficacy and Safety of a Bacillus Clausii Probiotic Strain Versus Placebo in the Treatment of Acute Diarrhoea in Children

Sanofi2 sites in 2 countries420 target enrollmentStarted: May 2004Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Phase 3
Status
Completed
Sponsor
Sanofi
Enrollment
420
Locations
2
Primary Endpoint
Duration of diarrhoea as counted from the first intake of the investigational product up to the first appearance of a loose stool followed by two-consecutive normal stools

Study Overview

Brief Summary

Primary objective:

  • To demonstrate the efficacy of a Bacillus clausii probiotic strain compared to placebo in children suffering from acute diarrhoea and treated for 7 days.

Secondary objective:

  • To evaluate the clinical safety of the Bacillus clausii probiotic strain versus placebo.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double

Eligibility Criteria

Ages
6 Months to 36 Months (Child)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Duration of diarrhoea as counted from the first intake of the investigational product up to the first appearance of a loose stool followed by two-consecutive normal stools

Secondary Outcomes

  • Number of infants/children with normal stools at D3, D4, D5, D6 and D7;Mean number of stools per day;Occurrence of vomiting episodes per day after enrolment;Parents'overall global assessment of efficacy at the end of the treatment;other safety criteria

Investigators

Sponsor
Sanofi
Sponsor Class
Industry

Study Sites (2)

Loading locations...

Similar Trials

TEDDY: Spores of Bacillus Clausii in Acute... | Clinical Trial